Arrhythmogenic Right Ventricular Cardiomyopathy — designated ARVC, also known as Arrhythmogenic Right Ventricular Dysplasia (ARVD) or Arrhythmogenic Cardiomyopathy (ACM) in its broader phenotypic spectrum, OMIM #107970 for the PKP2 variant and catalogued under multiple additional OMIM entries for the five primary desmosomal gene loci, a rare inherited cardiomyopathy with an estimated prevalence of 1 in 2,000 to 1 in 5,000 in the general population and an autosomal dominant inheritance pattern with markedly variable penetrance and expressivity — is caused in the majority of identifiable genetic cases by heterozygous loss-of-function mutations in desmosomal protein-encoding genes: PKP2 (plakophilin-2, chromosome 12p11, encoding a critical component of the cardiac desmosome that links desmin intermediate filaments to the desmosomal plaque and is mutated in approximately 70-80% of ARVC families with an identifiable causative variant in the United States and Northern Europe), DSP (desmoplakin, chromosome 6p24.3, the largest desmosomal protein and the only component that directly binds both plakophilins and intermediate filaments, with DSP mutations producing both ARVC and arrhythmogenic left ventricular cardiomyopathy), DSG2 (desmoglein-2, chromosome 18q12.1, the main desmosomal cadherin expressed in cardiac muscle, with biallelic DSG2 mutations causing a more severe recessive form), DSC2 (desmocollin-2, chromosome 18q12.1), and JUP (junction plakoglobin, chromosome 17q21, whose biallelic loss-of-function causes Naxos disease — the autosomal recessive syndromic form with cardiomyopathy, woolly hair, and palmoplantar keratoderma — while heterozygous JUP variants cause autosomal dominant ARVC); the fundamental pathomechanism involves desmosomal dysfunction at intercalated discs leading to cardiomyocyte detachment and death under mechanical stress, with replacement of the right ventricular free wall myocardium by fibrofatty fibrous tissue — the pathological hallmark fibrofatty replacement begins at the "triangle of dysplasia" (right ventricular outflow tract, right ventricular apex, and subtricuspid region) and progresses to diffuse right ventricular involvement and, in advanced disease, biventricular involvement; the disease follows a characteristic four-stage natural history: a concealed phase (subclinical fibrofatty replacement with preserved right ventricular function, during which sudden cardiac death from ventricular fibrillation may paradoxically occur, often in young athletes during high-intensity exercise), an overt electrical disorder phase (symptomatic ventricular arrhythmias — premature ventricular complexes, non-sustained VT, sustained VT with a left-bundle branch block morphology reflecting right ventricular origin, and ventricular fibrillation), a right ventricular dysfunction phase (progressive right ventricular enlargement and dysfunction, wall motion abnormalities — akinesia, dyskinesia, or aneurysm formation — detectable by echocardiography and cardiac MRI), and a biventricular heart failure phase (left ventricular involvement with biventricular heart failure in the subset of patients with advanced disease); the most feared complication is sudden cardiac death, which occurs predominantly during exercise-related sympathetic activation, making ARVC one of the leading causes of exercise-related sudden cardiac death in young athletes — exercise restriction is a cornerstone of ARVC management, with all competitive athletics prohibited and even vigorous recreational exercise restricted, because exercise accelerates disease progression and increases arrhythmia risk by augmenting mechanical stress on the abnormal desmosomal junctions; clinical diagnosis is established using the 2010 and updated 2020 Task Force Criteria incorporating echocardiographic and cardiac MRI findings, ECG abnormalities (T-wave inversions in V1-V4, epsilon waves, prolonged S-wave upstroke in V1-V3), signal-averaged ECG late potentials, ventricular arrhythmia characteristics, tissue characteristics on histopathology, and genetic findings; treatment centers on ICD implantation for secondary prevention (after sustained VT, VF, or resuscitated cardiac arrest) and for primary prevention in high-risk patients (defined by high arrhythmia burden, extensive RV dysfunction, syncope, or family history of sudden cardiac death), antiarrhythmic therapy (sotalol and amiodarone for VT suppression; beta-blockers for rate control and sympathetic blockade), catheter ablation (endocardial and epicardial VT ablation for drug-refractory symptomatic VT), heart failure management in biventricular phase (ACE inhibitors/ARBs, beta-blockers, diuretics), and cardiac transplantation for end-stage biventricular heart failure.
ARVC technology platforms — encompassing the inherited cardiomyopathy clinic platforms where genetic variant interpretation, Task Force Criteria scoring, and disease progression staging for PKP2, DSP, DSG2, DSC2, and JUP mutation carriers are conducted, the device clinic platforms managing ICD programming, remote monitoring of ICD shock logs and detected arrhythmia episodes, and device parameter optimization, the arrhythmia monitoring platforms conducting 24-hour ambulatory Holter monitoring and event recording for ventricular arrhythmia burden quantification, the cardiac imaging platforms performing echocardiography and cardiac MRI for right ventricular structure and function assessment, the electrophysiology laboratory platforms performing VT ablation procedures and programmed electrical stimulation, the sports medicine and exercise restriction counseling platforms managing activity limitation guidance and athlete-ARVC management, the genetic counseling platforms coordinating cascade screening among first-degree relatives of ARVC probands, the antiarrhythmic medication management platforms tracking sotalol QTc monitoring and amiodarone toxicity surveillance, and the advanced heart failure and cardiac transplant platforms managing end-stage biventricular disease — must maintain the availability and performance standards required by the ICD shock event surveillance urgency, the ventricular arrhythmia burden monitoring precision, the exercise restriction counseling acuity in athlete populations, the genetic family cascade screening coordination complexity, the serial cardiac MRI disease progression documentation rigor, and the Task Force Criteria reassessment discipline that define comprehensive ARVC management. This guide explains why ARVC care tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the exercise-related SCD risk, ICD-dependent arrhythmia management, and lifelong genetic family coordination requirements that characterize modern ARVC care.
Why ARVC Tech Platforms Require Specialized Monitoring Attention
ARVC management is defined by several distinctive care coordination challenges that make platform reliability a clinical imperative: the ICD shock event surveillance urgency — ICD-implanted ARVC patients generate remote monitoring transmissions documenting every detected episode, appropriate ICD therapy, ATP (anti-tachycardia pacing) delivery, and inappropriate shock event requiring device programmer review, medication adjustment, or urgent catheter ablation referral, making ICD remote monitoring platforms continuously critical for arrhythmia event detection and therapy appropriateness assessment; the exercise restriction enforcement urgency in athlete populations — ARVC disproportionately affects young competitive athletes because exercise accelerates fibrofatty replacement, augments VT risk, and is the trigger for exercise-related SCD in the concealed phase, making sports cardiology and exercise restriction counseling platform availability critical during the critical window between initial genetic diagnosis (or initial ECG/imaging abnormality) and formal ARVC diagnosis when an unaware athlete is at maximum risk; the ventricular arrhythmia burden monitoring intensity — 24-hour ambulatory Holter monitoring quantifying PVC burden (PVCs per 24 hours, PVC percentage, non-sustained VT runs, sustained VT episodes), done serially to track disease progression and guide antiarrhythmic therapy intensification, requires arrhythmia reporting platform availability for timely result review; the serial cardiac MRI disease progression monitoring obligation — right ventricular volume, ejection fraction, and regional wall motion abnormalities documented by cardiac MRI provide the structural disease staging backbone of ARVC management, with MRI findings used to update Task Force Criteria scores, time ICD implantation in subclinical mutation carriers, and identify left ventricular involvement signaling transition to biventricular phase; the genetic cascade screening coordination burden — ARVC follows autosomal dominant inheritance with 50% offspring transmission probability, and each newly diagnosed proband triggers cascade clinical and genetic evaluation of all first-degree relatives (parents, siblings, children), requiring ongoing coordination of genetic testing, ECG and Holter monitoring, and cardiac MRI in family members who are at 50% prior probability of carrying the familial pathogenic variant; and the Task Force Criteria reassessment discipline — ARVC diagnosis and subclinical carrier monitoring require periodic reassessment of the 2010 Task Force Criteria major and minor criteria across ECG, imaging, arrhythmia, histopathology, and genetic domains, with criteria updates triggering formal diagnostic reclassification from "possible" to "borderline" or "definite" ARVC.
ICD remote monitoring platforms are the highest-priority continuous monitoring obligation in ARVC. Appropriate ICD shocks require prompt programming review; inappropriate shocks require urgent therapy optimization to prevent recurrence; VT/VF episodes document disease progression. Monitor ICD remote monitoring platforms at 1-minute intervals, 24/7.
Ambulatory arrhythmia monitoring platforms carry the primary ventricular arrhythmia burden quantification function. PVC burden, non-sustained VT frequency, and sustained VT episodes are the primary metrics driving antiarrhythmic therapy intensification decisions and ablation referral timing in ARVC. Monitor at 1-minute intervals during clinical hours.
Cardiac MRI scheduling and reporting platforms must not fail during the annual disease progression assessment cycle. Right ventricular volumetric assessment by cardiac MRI is the gold standard for structural disease staging and Task Force Criteria major criterion scoring. Monitor at 1-minute intervals during radiology operational hours.
Exercise restriction and sports medicine platforms are most critical during the initial workup period before formal diagnosis. An ARVC mutation carrier continuing high-intensity exercise while awaiting formal diagnostic workup completion is at elevated risk for exercise-related SCD. Monitor at 1-minute intervals during clinical hours.
What to Monitor on an ARVC Tech Platform
Genetic Testing — Desmosomal Gene Panel
Monitor PKP2 sequencing records (next-generation sequencing of all PKP2 coding exons — PKP2 frameshift, nonsense, splice-site, and missense mutations; variant classification per ClinGen ARVC Expert Panel curated criteria; VUS resolution tracking), DSP sequencing records (desmoplakin mutations, which produce both ARVC and arrhythmogenic left ventricular cardiomyopathy phenotypes — DSP variants may be associated with predominantly left ventricular fibrosis and an arrhythmia phenotype without classic RV structural criteria, requiring genotype-aware diagnostic interpretation), DSG2 and DSC2 sequencing records, JUP sequencing records (with attention to Naxos disease biallelic recessive form versus heterozygous ARVC dominant form), and comprehensive ARVC gene panel records (additional non-desmosomal ARVC loci including TMEM43/LMNA/PLN/FLNC/RYR2 — RYR2 mutations cause CPVT and a minority of ARVC phenocopies), as well as family variant testing records (targeted single-variant testing of identified familial variant in first-degree relatives — parents, siblings, children of proband) at 1-minute intervals during laboratory hours. Alert immediately — delays in variant classification or family variant testing results create delays in exercise restriction counseling for relatives who may be mutation carriers participating in high-intensity competitive athletics.
ICD Remote Monitoring
Monitor ICD remote transmission records (daily automatic transmissions from subcutaneous ICD and transvenous ICD devices — transmitted episode logs, detected VT/VF episodes, ATP delivery records, shock delivery records, device sensing integrity checks, lead impedance trends), ICD appropriate therapy records (ATP efficacy for VT termination, appropriate shock delivery for VF or VT above programmed ATP zones — number of episodes per month, coupling interval, VT cycle length trends), ICD inappropriate therapy records (T-wave oversensing — a common ARVC problem because right ventricular T-wave inversions in V1-V4 create T-wave amplitude-to-QRS amplitude ratios that may trigger inappropriate oversensing in subcutaneous ICD devices with sensing vector traversing the right precordium; supraventricular tachycardia discrimination failure; lead noise), ICD battery status records (battery longevity estimation, replacement planning trigger at elective replacement indicator — ERI), device parameter optimization records (sensing vector selection for S-ICD patients to minimize T-wave oversensing; programming zone adjustments after ablation procedures), and post-ablation device reassessment records at 1-minute intervals, 24/7.
Ventricular Arrhythmia Burden — Holter and Event Monitoring
Monitor 24-hour Holter monitoring records (total PVC count per 24 hours; PVC percentage of total beats; morphology — LBBB inferior axis PVCs from RVOT origin; LBBB superior axis PVCs from RV apex or subtricuspid region; non-sustained VT run count, maximum duration, and cycle length; sustained VT episodes; ventricular fibrillation episodes; arrhythmia complexity trends over serial monitoring), extended event recording records (30-day event monitors or implantable loop recorders for paroxysmal symptom correlation — palpitations, presyncope, syncope, exertional symptoms), exercise stress testing records (VT inducibility during exercise or recovery — exercise-induced PVCs and LBBB-morphology VT are Task Force Criteria minor arrhythmic criterion; exertional SCD risk stratification), and electrophysiology study records (programmed electrical stimulation for VT inducibility — sustained monomorphic VT induction predicts ICD benefit; VT morphology mapping for ablation planning) at 1-minute intervals during arrhythmia reporting hours. Alert immediately — Holter report delivery failures that delay PVC burden quantification needed for clinic visit antiarrhythmic therapy adjustment create management gaps in high-burden patients with rapidly evolving disease.
Cardiac MRI — Right Ventricular Structure and Function
Monitor cardiac MRI right ventricular volumetric records (RV end-diastolic volume indexed to BSA — RVEDVI >110 mL/m² male or >100 mL/m² female as 2010 Task Force Criteria major criterion; RV end-systolic volume; RV ejection fraction — RVEF <40% as major criterion, 40-45% as minor criterion), regional right ventricular wall motion records (akinesia, dyskinesia, or aneurysm in RVOT, RV apex, or subtricuspid region — major criteria when co-occurring with electrocardiographic criteria; RV free wall motion abnormality extent and severity), late gadolinium enhancement records (LGE pattern in RV free wall, RV-LV junction, and left ventricular fibrosis — LGE extent and distribution as disease progression marker and SCD risk factor), biventricular involvement records (left ventricular LGE indicating advanced or biventricular phase ARVC; LV ejection fraction), and Task Force Criteria integration records (MRI imaging criteria combined with ECG, arrhythmia, histopathology, and genetic criteria — formal Task Force Criteria scoring per 2010 framework with 2020 modifications) at 1-minute intervals during radiology hours. Alert immediately — cardiac MRI result delivery failures that prevent Task Force Criteria updating prior to a clinic visit where ICD implantation decisions are being made are time-sensitive clinical disruptions.
ECG and Electrocardiographic Monitoring
Monitor 12-lead ECG records (T-wave inversions in V1-V4 in absence of RBBB — major criterion; T-wave inversions in V1-V2 and V4-V6 — minor criterion in adults with RBBB; epsilon waves — terminal notch at end of QRS in V1-V3 as major criterion; prolonged S-wave upstroke in V1-V3 ≥55 ms as minor criterion; QRS dispersion ≥40ms), signal-averaged ECG records (late potential detection — filtered QRS duration >114 ms; root mean square voltage <20 µV in last 40 ms of filtered QRS; terminal QRS duration <40 µV >38 ms), QTc monitoring records during sotalol therapy (QTc prolongation risk with sotalol — dose reduction or discontinuation triggered at QTc >500 ms), ECG serial comparison records (T-wave inversion progression, epsilon wave appearance on serial ECGs), and ECG monitoring in asymptomatic mutation-positive relatives (annual ECG with progressive T-wave inversion development signaling phenotypic expression and triggering Holter and MRI workup) at 1-minute intervals during clinical hours.
Exercise Restriction and Physical Activity Monitoring
Monitor exercise restriction counseling records (formal exercise restriction prescription — prohibition of competitive athletics, restriction of vigorous recreational exercise; physician-patient counseling documentation for both mutation-positive subclinical carriers and definite ARVC patients), physical activity logging records (wearable-integrated activity monitoring for high-risk ARVC patients and mutation-positive athletes to assess exercise restriction compliance), return-to-play prohibition documentation records (written athlete clearance denials for competitive sports participation — documentation required to prevent unauthorized return to competitive activity while workup is ongoing or after ARVC diagnosis), exercise prescription for permitted activity records (low-to-moderate intensity non-competitive walking, swimming, or cycling where permitted by physician individualized assessment — activity restriction varies by phenotype severity), and athlete-ARVC specific counseling records (documentation of athlete psychological support referral for adjustment to athletic identity loss following exercise restriction counsel) at 1-minute intervals during sports medicine and cardiology clinic hours. Alert immediately — exercise restriction counseling platform failures during the workup period for an athlete referred with an abnormal ECG who has not yet had MRI or formal Task Force Criteria assessment represent an unacceptable SCD risk window.
Antiarrhythmic Medication Management
Monitor beta-blocker therapy records (metoprolol, carvedilol, or nadolol for sympathetic blockade — dose, heart rate response, QTc on therapy), sotalol therapy records (Class III antiarrhythmic with beta-blocking activity — initiation in monitored inpatient or outpatient setting, QTc monitoring at 4-6 hours post-dose during initiation, serial QTc surveillance; dose adjustment for renal function; sotalol QTc prolongation causing torsades de pointes risk requires systematic monitoring), amiodarone therapy records (thyroid function testing — TSH every 6 months; pulmonary function testing — annual or for new respiratory symptoms; liver function tests — annual; ophthalmology for corneal deposits and optic neuropathy; amiodarone dose records), catheter ablation records (endocardial electroanatomic VT mapping and ablation; epicardial access records for epicardial substrate ablation; ablation success documentation — VT non-inducibility post-ablation; procedural complication records — cardiac tamponade, pericarditis), and antiarrhythmic escalation records (step-up from beta-blocker to sotalol to amiodarone plus ablation) at 1-minute intervals during clinic and laboratory hours.
Family Cascade Screening
Monitor proband family structure records (first-degree relatives identified for cascade screening — parents, full siblings, children), relative genetic testing records (targeted single-variant testing for familial pathogenic variant; result disclosure records; variant-positive relative identification), ECG and Holter records for variant-positive relatives (baseline ECG, T-wave inversion assessment; Holter for PVC burden quantification; signal-averaged ECG), cardiac MRI records for variant-positive relatives (baseline RV volumetric assessment; serial MRI in mutation-positive relatives with any cardiac symptoms, ECG changes, or Holter-detected arrhythmias), clinical phenotyping schedule records (annual or biennial evaluation of mutation-positive relatives for ARVC phenotype expression — ECG, Holter, and echocardiography annually; cardiac MRI every 2-5 years or more frequently if phenotype developing), and mutation-negative relative records (removal from intensive surveillance after confirmed absence of familial variant) at 1-minute intervals during genetic counseling and cardiology clinic hours.
Task Force Criteria Reassessment and Disease Staging
Monitor Task Force Criteria documentation records (formal scoring of 2010 Task Force Criteria major and minor criteria across five domains: ECG, imaging, histopathology, arrhythmia, and genetic; classification as definite/borderline/possible ARVC; 2020 modification for gene-specific criteria and LV involvement), disease progression staging records (concealed phase — mutation positive, Task Force criteria not met, normal function; early electrical phase — arrhythmia criteria met, normal or mildly abnormal structure; overt RV dysfunction phase — structural major criteria met; biventricular phase — LV involvement on imaging), SCD risk stratification records (ARVC-SCD risk calculator inputs: age, sex, non-sustained VT, syncope, prior sustained VT/VF, RV dysfunction severity, LV dysfunction — annual risk calculation for ICD primary prevention decisions), and ICD implantation decision records (electrophysiology consultation for primary prevention ICD recommendation based on Task Force Criteria completion, arrhythmia burden, family history of SCD, and SCD risk model output) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. ARVC management coordinates across inherited cardiomyopathy cardiology (genetic result integration, Task Force Criteria assessment, disease staging), cardiac electrophysiology (ICD implantation and programming, VT ablation, device clinic follow-up), remote device monitoring services (ICD transmission review), cardiac MRI (RV volumetric staging, LGE assessment), echocardiography (serial RV function assessment, biventricular phase detection), ambulatory monitoring (Holter, event monitors, ILR), cardiac genetic testing and counseling (proband testing, family cascade screening, variant classification), sports medicine (exercise restriction counseling, athlete-ARVC management), antiarrhythmic pharmacy (sotalol QTc monitoring, amiodarone toxicity surveillance), cardiac catheterization and ablation laboratory (VT ablation), and cardiac transplant services (end-stage disease) — authentication failures across this distributed multi-specialty ARVC management infrastructure disrupt the ICD-centered, exercise-restricted, genetically-informed disease management program that ARVC patients require from genetic diagnosis through lifelong arrhythmia and structural disease surveillance.
SSL Certificates
Monitor SSL certificate expiry across all inherited cardiomyopathy clinic platforms, ICD remote monitoring services, ambulatory Holter and event monitoring portals, cardiac MRI scheduling and reporting systems, genetic testing laboratory portals, exercise restriction counseling documentation systems, antiarrhythmic pharmacy monitoring portals, and cardiac transplant coordination platforms. Certificate errors disrupt ICD remote monitoring transmissions, arrhythmia report delivery, and cardiac MRI result access at the moments when those results inform time-sensitive clinical management decisions.
HIPAA and Genetic Information Privacy Considerations
ARVC technology platforms handle GINA-protected genetic information (PKP2, DSP, DSG2, DSC2, and JUP pathogenic variant results with direct insurance and employment discrimination implications), cardiac device data with precise cardiac rhythm and physical activity information from ICD remote monitoring transmissions, family pedigree information generated through cascade screening that necessarily documents genetic relationships and carrier status among non-patient family members, and sudden cardiac death risk stratification records including SCD risk model outputs and ICD implantation decision documentation.
The exercise restriction documentation for competitive athletes creates particularly sensitive records — athlete-patients who receive exercise restriction counseling may have legitimate confidentiality interests in preventing their employers (professional sports organizations), coaches, teammates, or public media from learning of their ARVC diagnosis. ARVC platforms must enforce strict role-based access controls preventing unauthorized disclosure of athlete-patient genetic diagnoses, exercise restriction orders, and SCD risk stratification records.
Family cascade screening generates genetic information about individuals who may not have consented to disclosure — the genetic testing of a proband identifies the pathogenic variant and the risk to first-degree relatives, creating an ethical tension between the proband's right to privacy and relatives' right to know their risk for a potentially fatal condition. Cascade screening workflows must document family consent and disclosure processes in compliance with GINA and relevant state genetic privacy statutes.
Alerting Strategy for ARVC Tech Platforms
Immediate 24/7 alerting for ICD remote monitoring platforms: Appropriate and inappropriate ICD shocks require immediate attention — appropriate shocks document disease progression and may trigger therapy intensification; inappropriate shocks cause psychological harm and may require urgent programming change.
Immediate 24/7 alerting for acute arrhythmia event protocols: VT storm, repeated ICD shocks, or symptomatic sustained VT in ARVC patients requires 24/7 electrophysiology emergency access.
Immediate clinical-hours alerting for ambulatory arrhythmia monitoring platforms: Holter and event monitoring result delivery drives antiarrhythmic therapy adjustment decisions at each clinic visit.
Immediate clinical-hours alerting for exercise restriction counseling platforms: Exercise restriction documentation failures during the athlete diagnostic workup window represent active SCD risk exposure.
Immediate clinical-hours alerting for cardiac MRI platforms: RV volumetric staging results are the primary structural criterion driving Task Force Criteria completion and ICD implantation decisions.
Immediate clinical-hours alerting for genetic cascade screening platforms: Variant testing result delays for first-degree relatives who may be participating in high-intensity athletics represent life-threatening information gaps.
Sustained-failure alert (10–15 minutes): Antiarrhythmic medication monitoring (sotalol QTc, amiodarone toxicity), Task Force Criteria documentation records, family pedigree and cascade tracking records.
30-day advance warning: SSL certificates across all domains.
Status Page for ARVC Care Team Communication
A real-time status page gives inherited cardiomyopathy cardiologists managing Task Force Criteria scoring and disease staging, cardiac electrophysiologists monitoring ICD transmissions and planning VT ablation, device clinic nurses reviewing daily remote monitoring transmissions, cardiac MRI radiologists providing RV volumetric staging reports, sports medicine physicians enforcing exercise restriction for athlete-patients, genetic counselors coordinating family cascade screening programs, ambulatory monitoring laboratories delivering Holter reports, and antiarrhythmic pharmacy monitoring services immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in ICD remote monitoring failure escalation protocols, athlete-ARVC exercise restriction counseling workflows, and cardiac transplant coordination pathways for patients transitioning to biventricular end-stage disease.
Vigilmon Setup for ARVC Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | ICD remote monitoring transmissions | 1 min | Slack + PagerDuty (24/7) | | ICD appropriate/inappropriate therapy logs | 1 min | Slack + PagerDuty (24/7) | | Acute VT storm emergency protocol | 1 min | Slack + PagerDuty (24/7) | | Desmosomal gene panel (PKP2/DSP/DSG2/DSC2/JUP) | 1 min | Slack + PagerDuty (lab hours) | | Family variant cascade testing | 1 min | Slack + PagerDuty (clinical hours) | | 24-hour Holter arrhythmia burden reporting | 1 min | Slack + PagerDuty (clinical hours) | | Extended event and ILR monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Exercise stress VT inducibility testing | 1 min | Slack + PagerDuty (clinical hours) | | Exercise restriction counseling documentation | 1 min | Slack + PagerDuty (clinical hours) | | Cardiac MRI scheduling and RV volumetric reporting | 1 min | Slack + PagerDuty (radiology hours) | | Echocardiography RV function assessment | 1 min | Slack + PagerDuty (radiology hours) | | 12-lead ECG and signal-averaged ECG | 1 min | Slack + PagerDuty (clinical hours) | | Sotalol QTc monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Amiodarone toxicity surveillance | 1 min | Slack + PagerDuty (clinical hours) | | VT catheter ablation procedure records | 1 min | Slack + PagerDuty (clinical hours) | | Task Force Criteria scoring and staging | 1 min | Slack + PagerDuty (clinical hours) | | SCD risk stratification records | 1 min | Slack + PagerDuty (clinical hours) | | Family cascade clinical evaluation scheduling | 2 min | Slack (business hours) | | Cardiac transplant coordination (end-stage) | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure ICD remote monitoring platforms with immediate 24/7 alerting — detecting appropriate and inappropriate shocks is the highest-priority continuous monitoring obligation in ARVC
- Add acute VT storm emergency protocol platforms with 24/7 alerting
- Configure desmosomal gene panel (PKP2/DSP/DSG2/DSC2/JUP) testing platforms with immediate laboratory-hours alerting
- Add family variant cascade testing platforms with immediate clinical-hours alerting — variant-positive relatives in competitive athletics require urgent exercise restriction counseling
- Configure 24-hour Holter arrhythmia burden reporting platforms with immediate clinical-hours alerting
- Add exercise restriction counseling documentation platforms with immediate clinical-hours alerting — failures during the athlete diagnostic workup window represent active SCD risk
- Configure cardiac MRI scheduling and RV volumetric reporting platforms with immediate radiology-hours alerting
- Add echocardiography RV function assessment platforms with immediate radiology-hours alerting
- Configure 12-lead ECG and signal-averaged ECG platforms with immediate clinical-hours alerting
- Add sotalol QTc monitoring platforms with immediate clinical-hours alerting — QTc prolongation >500 ms is an urgent dose-reduction indication
- Configure amiodarone toxicity surveillance platforms with immediate clinical-hours alerting
- Add VT catheter ablation procedure records with immediate clinical-hours alerting
- Configure Task Force Criteria scoring and SCD risk stratification platforms with immediate clinical-hours alerting
- Add family cascade clinical evaluation scheduling platforms with sustained-failure alerting
- Configure cardiac transplant coordination platforms for biventricular end-stage patients with sustained-failure alerting
- Enable SSL certificate monitoring across all ICD monitoring, genetic testing, cardiac imaging, arrhythmia monitoring, and transplant coordination domains with 30-day advance email warning
Conclusion
ARVC technology platforms are embedded in clinical decisions where ICD remote monitoring platform availability at 2:47 AM on a Tuesday matters when the remote monitoring service receives a transmission from the subcutaneous ICD of a 28-year-old PKP2 mutation carrier who was diagnosed with definite ARVC two years ago after a resuscitated cardiac arrest during a marathon and who has had the SICD programmed with an aggressive shock zone at 200 BPM — and the transmission documents three consecutive appropriate 80-joule shocks over a 4-hour period for spontaneous VF episodes — and the on-call electrophysiologist covering the remote monitoring service must access the transmitted episode electrograms, confirm appropriate shock delivery versus inappropriate oversensing, and determine whether the VF storm requires urgent hospital admission and IV antiarrhythmic therapy loading or whether the episodes can be managed with amiodarone dose escalation on an outpatient basis — a clinical decision that cannot be made if the remote monitoring platform is unavailable at the moment the transmission arrives and the electrophysiologist cannot view the intracardiac electrograms confirming VF onset, shock delivery, VF termination, and post-shock rhythm; where exercise restriction counseling platform availability on the morning when a 19-year-old Division I basketball player's cardiologist is attempting to document the formal exercise restriction counseling session that must occur before the player's institution learns of the ARVC diagnosis and the player's participation in the spring tournament — and the counseling documentation platform must allow the cardiologist to create the written exercise restriction prescription, the player's witnessed acknowledgment of the SCD risk of continued high-intensity athletics, the psychological support referral, and the institutional athletic training staff notification plan — because this documentation is both the clinical record and the medico-legal evidence that the cardiologist fulfilled the standard of care by counseling an athlete-patient about a genetically confirmed life-threatening condition before that patient returns to practice; and where cardiac MRI scheduling platform availability when the inherited cardiomyopathy clinic coordinator is booking the annual serial cardiac MRI for a 35-year-old DSP heterozygous mutation carrier who showed a borderline right ventricular ejection fraction of 45% on last year's MRI and who the managing cardiologist has told will receive an ICD if this year's RVEF is below 40% or if significant new late gadolinium enhancement appears in the left ventricular free wall — and the MRI scheduling platform must book the scan within the annual surveillance window so the clinic visit scheduled for six weeks after the MRI can incorporate the updated volumetric data into the ICD implantation decision — cannot be disrupted by platform failures that defer the MRI beyond the surveillance window and force the cardiologist to make an ICD implantation decision without the updated structural data that is the primary basis for that recommendation. An ICD remote monitoring platform that leaves an electrophysiologist unable to view transmitted VF storm electrograms at 3 AM, an exercise restriction counseling platform that delays written counseling documentation for an athlete-patient in the critical pre-diagnosis window, a cardiac MRI scheduling system that allows serial volumetric surveillance to slip beyond its annual window in a patient awaiting ICD implantation criteria completion — these are not IT incidents. They are clinical disruptions in the management of one of the most dangerous inherited cardiac conditions in humans, whose exercise-triggered SCD risk in young athletes, ICD-dependent arrhythmia management, and lifelong family cascade screening obligations make continuous platform availability the operational foundation of a disease management program that cannot afford gaps during ICD transmission reviews, athlete counseling, or structural staging assessments.
Uptime monitoring gives ARVC tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to cardiologists managing lifelong ICD surveillance and Task Force Criteria staging, electrophysiologists monitoring daily remote ICD transmissions and planning VT ablation, sports medicine physicians enforcing exercise restriction for athlete-patients with newly diagnosed ARVC, cardiac MRI radiologists providing annual RV volumetric staging reports, genetic counselors coordinating cascade screening in first-degree relatives who may be asymptomatic mutation carriers in competitive athletics, and compliance auditors reviewing inherited cardiomyopathy program performance that platform operational reliability matches the 24/7 ICD surveillance intensity, the exercise-restriction enforcement acuity, the serial cardiac MRI staging precision, and the family cascade screening coordination complexity of modern ARVC management.
Start monitoring your ARVC care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #ARVC #ARVD #ArrhythmogenicCardiomyopathy #PKP2 #DSP #DSG2 #DSC2 #JUP #desmosome #ICD #ventricularTachycardia #suddenCardiacDeath #athleteHeart #exerciseRestriction #cardiacMRI #rightVentricular #fibrofattyReplacement #TaskForceCriteria #geneticCascadeScreening #inheritedCardiomyopathy #GINA #HIPAA #healthtech #digitalhealth #uptime #sre